I would echo your sentiments in regards to extraction companies. I also feel like these companies have not had the inflated PPS related to the upcoming Cannabis 2.0 changes in Canada that the retailers have. If I’m right about that, then that added demand of new players entering the space and needing extraction services will be gravy on top of what we already have.
Neptune is interesting because they have been very tight-lipped. They haven’t announced the dollar value of their extraction deals whereas MediPharm has. They also have not provided any forward guidance. So it is a case where the dollar volume is already very low and the true value needs to be pieced together through careful research and analysis.
Once revenues become realized (remember, shipments for both of those deals — Tilray and TGOD — were stated to begin in September) and/or some forward guidance is given, that will make the value here easily digestible and bring in new investors. Until then, we will blow around like a leaf in the wind depending on what the sector does.
I myself have been using this as an opportunity to average down and with the long-term vision in focus I see this recent slide as a positive short-term opportunity rather than lamenting it as unrealized losses.
News 
Market Data 
Discover 
